Muscle mass seems to be a prognostic marker in patients with liver cirrhosis. However, reported methods to quantify muscle mass are heterogeneous, consented cutoff values are missing, and most studies have used computed tomography. This study evaluated fat-free muscle area (FFMA) as a marker of sarcopenia using magnetic resonance imaging (MRI) in patients with decompensated cirrhosis with transjugular intrahepatic portosystemic shunt (TIPS). The total erector spinae muscle area and the intramuscular fat tissue area were measured and subtracted to calculate the FFMA in 116 patients with cirrhosis by TIPS and MRI. The training cohort of 71 patients compared computed tomography-measured transversal psoas muscle thickness with FFMA. In 15 patients MRI was performed before and after TIPS, and in 12 patients follistatin serum measurements were carried out. The results on FFMA were confirmed in a validation cohort of 45 patients. FFMA correlated with follistatin and transversal psoas muscle thickness and showed slightly better association with survival than transversal psoas muscle thickness. Gender-specific cutoff values for FFMA were determined for sarcopenia. Decompensation (ascites, overt hepatic encephalopathy) persisted after TIPS in the sarcopenia group but resolved in the nonsarcopenia group. Sarcopenic patients showed no clinical improvement after TIPS as well as higher mortality, mainly due to development of acute-on-chronic liver failure. FFMA was an independent predictor of survival in these patients. Conclusion: This study offers an easy-to-apply MRI-based measurement of fat-free muscle mass as a marker of sarcopenia in decompensated patients; while TIPS might improve sarcopenia and thereby survival, persistence of sarcopenia after TIPS is associated with a reduced response to TIPS and a higher risk of acute-on-chronic liver failure development and mortality. (HEPATOLOGY 2018; 67:1014-1026. P ortal hypertensive complications such as refractory ascites and variceal bleeding are frequent causes of acute decompensation in liver cirrhosis.
liver failure (ACLF), a recently described syndrome with high short-term mortality. (5, 6) In this patient population, meticulous selection and management require good clinical markers. Sarcopenia is common in these decompensated patients, and methods to evaluate muscle mass have recently proposed cutoffs, especially for patients on the waiting list for liver transplantation (LT). (7) (8) (9) Especially, cross-sectional imaging, e.g., magnetic resonance imaging (MRI) and computed tomography (CT), could evaluate skeletal muscle mass and diagnose sarcopenia. (10) This is convenient because MRI or CT scans are routinely performed for several clinical reasons in decompensated patients.
It has been proposed that CT scans of different muscle parameters enable diagnosis of sarcopenia, e.g., the psoas cross-sectional area, (11) the transversal psoas muscle thickness (TPMT) normalized by height, (12) and the third lumbar vertebra muscle index. (13) (14) (15) (16) In several methods, special software is required. CT has several drawbacks, such as radiation exposure and the risk of inducing or aggravating kidney injury (contrastinduced nephropathy) due to iodinated contrast agents. (17) For specific medical scenarios (e.g., accurate detection of hepatocellular carcinoma), MRI is nowadays increasingly used in chronic liver disease. (18) Moreover, not only total muscle mass but also quality or activity of the muscle seem to be important, as reflected by different myokines, such as follistatin, which has been used as a surrogate parameter. (19) (20) (21) To the best of our knowledge, no study has used MRI and specifically examined the quality of the muscles as a read-out for sarcopenia in decompensated cirrhosis to date.
This study aimed to (1) offer an MRI method to accurately assess sarcopenia and (2) explore the prognostic value of this method to predict ACLF and survival in patients with decompensated cirrhosis receiving TIPS.
Patients and Methods

STUDY POPULATION
For this retrospective study, we screened 677 patients receiving TIPS from December 1993 to September 2014 to identify 116 patients with MRI (Fig.  1A) . A total of 561 patients were excluded, 556 without abdominal MRI and 5 due to poor image quality. The follow-up period was documented for 3 years after the TIPS procedure. Biochemical blood analyses were performed using standard tests. The local ethics committee of the University of Bonn approved the study (029/13), and all patients agreed and signed an informed written consent in accordance with the Helsinki Declaration for the procedures they underwent.
In order to compare the novel techniques with published data on sarcopenia, in 71 patients the muscle area (MA) was assessed in addition to cross-sectional MRI, also using TPMT in the CT scan. (12) Moreover, of the patients who underwent a TIPS procedure from June 2007 to May 2014, 15 had received MRI before and after TIPS (Table 1 ) and in 12 patients additional blood samples were collected to analyze follistatin (Fig.  1A) . A validation cohort of 45 patients with only MRI was used to validate the MRI findings (Fig. 1A) .
Finally, the whole cohort of 116 patients with MRI was analyzed (Fig. 1B) . Mean and median follow-up after MRI were 17 6 2 months (no sarcopenia group 20 6 2 months, sarcopenia group 13 6 2 months) and 10 (0-68) months (no sarcopenia group 13 [0-80] months, sarcopenia group 7 [0-65] months), respectively (Table 2) .
ARTICLE INFORMATION:
ASSESSMENT OF SKELETAL MA IN MRI
A commercially available clinical 3.0-Tesla MRI system (Ingenia 3.0 T; Philips Healthcare, Best, The Netherlands) or a 1.5-Tesla MRI system (Ingenia 1.5 T; Philips Healthcare) was used. The different magnetic field strengths (3.0 or 1.5 T) did not impact the results because both are equally effective at depicting the anatomy and thus muscle fat distribution. All patients underwent a standardized MRI sequence protocol, including axial T2-weighted turbo spin echo sequences with and without spectral presaturation attenuated by inversion recovery for fat suppression, axial T1-weighted fast field echo in-phase and opposed-phase sequences, diffusion-weighted imaging, and axial dynamic contrast-enhanced fat-suppressed T1-weighted gradient echo sequences. For image analysis, T2-weighted turbo spin echo sequences were transferred to a separate workstation. Sequence parameters for T2-weighted turbo spin echo were as follows: echo time, 80 ms; repetition time, dependent on respiratory rate; acquired voxel size, 1.5 3 1.5 3 5 mm. The sequences were examined by four physicians (M.P., M.B., J.L., G.K.). The interreader variability was very low (intraclass correlation coefficient for the assessment of MA was 0.986 (95% confidence interval 0.970-0.994; P 5 0.000). Agreement on classification of sarcopenic and nonsarcopenic patients was 1.000 (P < 0.001). Also, the differences between 1.5T and 3T were negligible. We chose a cross section, which is routinely captured in imaging of the liver, not prone to high variability and easy to identify. In 90% of our patients the position of the superior mesentery artery was located at the level of the L1 vertebra, while in 5% of our patients it was located at Th12 or L2. Consequently and due to the fact that main visceral arteries are largely immobile and rarely show interindividual differences, the radix of the superior mesenteric artery was chosen as a landmark for the measurement of the erector spinae muscle ( Fig. 2A) . (22, 23) We measured both sides to avoid confounders due to individual local inflammatory or degenerative processes or differences between the two sides resulting from dominant use of one side, postural fitness, and preferences. We evaluated side differences of the erector spinae muscle area (fat-free muscle area [FFMA] ) and found that in 13 patients the right MA and left MA were similar, 48 patients had more pronounced MA on the left side (FFMA left -FFMA right 5 6.2% [1.0-27.4%]), while 55 patients had more muscle on the right side (FFMA left -FFMA right 5 -6.7% [1.2-58.2%]).
The resulting DICOM images were analyzed with Image J software (Wayne Rasband, National Institutes of Health), which enables calculation of defined crosssectional areas (square millimeters). It also allows distinction between striated muscular and fatty tissue within the total MA, which we used to determine myosteatosis. Muscle and fat tissue were semiautomatically quantified based on MRI signal, i.e., hypointense for striated muscle and hyperintense for fat. Next, the images were transformed into binary files, and the fatty tissue area was calculated by adding up tissue pixels and multiplying by pixel surface area. The interobserver variability was negligible. The identified area of fatty tissue was then subtracted from the total MA to obtain the FFMA (Fig. 2B,C) . Mean distance of pre-TIPS MRI to TIPS was 47 6 12 days, while mean distance of TIPS to post-TIPS MRI was 519 6 50 days.
ASSESSMENT OF SKELETAL MUSCLE AREA IN CT
Commercially available CT imaging systems (Philips Brilliance 64 or Philips Brilliance 256 iCT; Philips Healthcare) were used. As it is the simplest parameter to obtain without special software, we examined the TPMT normalized by height as described in cross-sectional images on the level of the umbilicus. (12) In our cohort, the umbilicus was located at the level of L4 in 70%, L5 in 20%, and L3 in 10% of patients. The mean time interval between CT and MRI was 117 6 16 days.
ASSESSMENT OF FOLLISTATIN
In 12 patients, follistatin levels were assessed in peripheral blood using enzyme-linked immunosorbent assay (R&D Systems DY 669 Human Follistatin; Bio-Techne GmbH, Wiesbaden, Germany) according to the manufacturer's guidelines.
STATISTICAL ANALYSIS
Descriptive statistics were computed for all variables. Nonparametric testing was used to compare different groups when suitable. Paired nonparametric testing was used to compare data before and after the TIPS procedure of the same patients. Metric variables were correlated using Spearman's correlation. Inter-reader variability was analyzed by intraclass correlation coefficient. Agreement on classification of sarcopenia and no sarcopenia between the raters was assessed using kappa statistics. The prognostic value and selection of cutoff values of skeletal muscle area were analyzed using receiver operating characteristics with 3-year survival as the endpoint. Kaplan-Meier curves with log-rank tests were used to examine the impact of MA on survival. Univariate and multivariate risk factor analyses were performed with Cox regression. Multivariate analysis included all values with P < 0.05. Continuous variables are presented as median (range), if not otherwise specified. Categorical variables are presented as absolute cases or percentage. All data were analyzed using SPSS (version 24; IBM, Armonk, NY) and plotted using Prism (version 6; GraphPad, La Jolla, CA).
Results
GENERAL CHARACTERISTICS AND SARCOPENIA DIAGNOSED BY MRI AND CT IN TRAINING COHORT
The training cohort of 71 patients (42 men) had a median age of 58 and a range of 18-78 years. The main etiology of liver cirrhosis was alcoholic liver disease in 51 patients and chronic viral hepatitis in 9 patients. The indication for TIPS placement was refractory ascites in 34 patients and variceal bleeding in 26, and 11 patients received TIPS for both indications (Supporting Table S1 ). To confirm findings from the training cohort, a validation cohort of 45 patients was included. Between the validation and the training cohorts no major significant changes were found in general demographics, except for etiology. Briefly, the validation cohort included 27 male patients with a median age of 59 and a range between 26 and 79 years. Twenty-two patients had alcoholic cirrhosis, a significantly lower portion than in the training cohort, and 9 patients presented with chronic viral hepatitis. Reason for TIPS was refractory ascites in 28 patients, variceal bleeding in 10 patients, and both indications in 7 patients (Supporting Table S1 ). Laboratory parameters, such as serum sodium, creatinine, bilirubin, albumin, international normalized ratio (INR), white blood cell count, C-reactive protein, and prognostic scores [CLIF-C AD]) did not differ significantly between the training and the validation cohorts (Supporting Table S1 ). Receiver operating characteristics analysis ( Fig. 3A ) with 3-year survival as the endpoint showed similar areas under the curve (AUC) for both MRI parameters (MA and FFMA), while CT-assessed TPMT showed the lowest AUC. While TPMT was normalized for height, (12) the normalization for height, weight, or body mass index of the MRI parameters MA and FFMA did not improve their AUC (data not shown). Using the gender-specific receiver operating characteristic curves, we received even higher AUC for FFMA (AUC male patients, 0.817; 95% confidence interval, 0.684-0.949; P < 0.001; AUC female patients, 0.804; 95% confidence interval, 0.592-1.000; P < 0.05). We then determined gender-specific cutoff values. In male patients MA <3,523 mm 2 and FFMA <3,197 mm 2 , and in female patients MA <3,153 mm 2 and FFMA <2,895 mm 2 were found optimal to diagnose sarcopenia. TPMT cutoff values were chosen at 16.8 cm/m for both male and female patients as described.
Diagnosis of sarcopenia in the three different techniques was associated with significantly higher 3-year mortality (Fig. 3B-D) . Regarding diagnosis of sarcopenia using MA and FFMA, 1 patient was misclassified, while comparison between FFMA and TPMT identified that 4 patients were misclassified.
VALIDATION OF FFMA
Using the above-mentioned cutoff values for MA and FFMA, in the validation cohort sarcopenia identified patients with significantly worse 3-year survival (Fig. 4A,B) , while FFMA performed slightly better than MA and was therefore used for further analysis.
FFMA BEFORE AND AFTER TIPS
In 15 patients, FFMA before and after TIPS was assessed ( median gain in MA of 605 mm 2 (234-2,001), while 4 had decreased MA or a median loss in MA of 283 mm 2 (176-612) after TIPS. Interestingly, patients with muscle loss after TIPS showed significantly worse survival (Fig. 4D ). Three out of 4 patients with muscle loss died during follow-up compared to only 1 of 11 patients with muscle gain after TIPS (P < 0.05). After TIPS, 5 patients were still classified as sarcopenic and 10 patients were classified as nonsarcopenic according to the FFMA cutoffs mentioned above. Nonsarcopenic patients showed significantly better survival, suggesting that persistence of sarcopenia after TIPS is associated with worse survival (Fig. 4E ). Between patients with muscle gain and muscle loss after TIPS, there was no significant difference in demographics, laboratory parameters, prognostic scores, and clinical features (hepatic encephalopathy [HE], ascites) before TIPS. However, after TIPS, patients with muscle loss showed significantly worse laboratory parameters (serum albumin, INR, white blood cell count) as well as higher MELD, MELD-Na, Child-Pugh, and CLIF-C AD scores (Table 1) . Importantly, in patients with muscle gain, the occurrence of HE decreased, whereas this was not the case in patients with muscle loss (Table 1) .
MRI-MEASURED MA CORRELATES WITH FOLLISTATIN LEVELS
Follistatin levels from blood samples of 12 patients taken at the time of the TIPS procedure strongly correlated to left (R 5 0.7, P 5 0.1), right (R 5 0.9, P 5 0.04), and total (R 5 0.9, P 5 0.04) MA assessed using MRI, suggesting that this method assessed active muscle amount in these patients.
FFMA-DEFINED SARCOPENIA IS ASSOCIATED WITH ORGAN DYSFUNCTION AND ACLF AFTER TIPS
For further analyses the training and validation cohorts were merged to provide a larger cohort of 116 TIPS patients with MRI ( Table 2 ). The general demographics and etiologies of cirrhosis did not significantly differ between sarcopenic and nonsarcopenic patients. The only differences were in indication for TIPS and portal systemic pressure gradient, whereby a larger proportion of sarcopenic patients received TIPS for refractory ascites and therefore had lower portal systemic pressure gradient before TIPS than nonsarcopenic patients ( Table 2 ). Absence of sarcopenia was associated with a better response to ascites and recovery of serum sodium and albumin levels after TIPS, while in sarcopenic patients ascites persisted and neither serum sodium nor albumin levels recovered (Supporting Fig. S1A ; Table 3 ). This was paralleled by a strong correlation of FFMA with serum protein levels (Supporting Fig. S1B) . Similarly, serum bilirubin, INR, and alanine aminotransferase levels increased significantly in sarcopenic patients, while in nonsarcopenic patients INR and alanine aminotransferase remained stable and bilirubin increased to a lesser degree ( Table 3) .
The incidence of episodes of overt HE was significantly higher in sarcopenic patients before and after TIPS. Interestingly, TIPS significantly reduced the frequency of episodes of overt HE in the nonsarcopenia group, while no change was observed in the sarcopenia group (Supporting Fig. S1C ; Table 3 ). Moreover, FFMA strongly correlated to performance on the number connection test for assessment of minimal HE (Supporting Fig. S1D ).
The increase of the MELD and the MELD-Na scores after TIPS procedure was higher in the sarcopenia group than in the nonsarcopenia group (Supporting Fig. S2A,B ; Table 3 ). Interestingly, sarcopenic patients presented a higher white blood cell count (Table 3) , which was also associated with a higher CLIF-C AD score, associated with higher risk of developing ACLF. Importantly, after TIPS, the CLIF-C AD score decreased in nonsarcopenic patients but remained high in sarcopenic patients (Supporting Fig. S2C ).
SARCOPENIA IS ASSOCIATED WITH HIGHER RISK OF ACLF AND DEATH AFTER TIPS
Overall, 26 patients died and 9 were transplanted (Fig. 1B) . Sarcopenic patients showed worse 3-year survival compared to nonsarcopenic patients (Fig. 4F) . Most patients died of ACLF (78%), which was triggered in 60% by infection, in 8% by bleeding, and in 10% by circulatory failure. The other deceased patients died from unknown reasons or carcinoma. There was no significant difference in the causes of death or TIPS dysfunction between the sarcopenia and the nonsarcopenia groups (P > 0.05, data not shown).
Univariate Cox regression analysis identified MA and FFMA as significantly associated with survival, inter alia with the expected prognostic scores (MELD, MELD-Na, and CLIF-C AD) and age (Table 4) . Multivariate Cox regression analysis, including all significant parameters from univariate analysis, identified FFMA and the CLIF-C AD score as independent predictors of mortality. Of note, MA was not independently associated with mortality, although classification for sarcopenia or nonsarcopenia was similar when using MA and FFMA.
Only 9 patients underwent LT; therefore, competing risk analysis with LT as the endpoint was not performed.
Discussion
This study demonstrates in a training cohort and a validation cohort that MRI assessment of FFMA identifies clinically relevant sarcopenia in a large cohort of patients with decompensated cirrhosis receiving TIPS. Besides describing and confirming the clinical impact of sarcopenia, this study shows that persistence of sarcopenia after TIPS impairs response to TIPS and increases the risk of developing ACLF and death. For assessment of sarcopenia, a cross-sectional MA is usually described. (10) However, its assessment has been performed in different muscle groups and at different levels, mainly using CT scans. (8, 11, 12, 14) The definition of reference values is a clinical requirement as stated by the European Working Group on Sarcopenia. (7) Simple anthropometric tests lack reproducibility and precision because in patients with cirrhosis they may be influenced by ascites and edema. (8) Although MRI is more demanding and costly than a CT scan, on many occasions CT scans may not be appropriate in these patients. Also, performing a CT scan with the intention of analyzing sarcopenia may be considered unethical due to radiation exposure. However, routine contrast-enhanced imaging CT or MRI for hepatocellular carcinoma screening or evaluation for LT or TIPS is clinically required in almost all patients with decompensated cirrhosis. In a number of patients, a CT scan might even be dangerous due to the risk of contrast medium-induced renal failure. (15) Therefore, liver MRI has been emerging as a more suitable imaging method in patients with cirrhosis. However, data regarding sarcopenia in decompensated liver cirrhosis are scarce. (24) This study provides an easy and useful marker of sarcopenia using MRI of the erector spinae muscle area on the level of the radix of the superior mesenteric artery, which is always in the window of liver MRI. Indeed, choosing this landmark for use in the analysis was motivated by the fact that this structure is easy to identify and that it is always in the MRI window of liver imaging. Importantly, to reduce the possible confounding role of ascites due to possible artifacts in the MRI, we selected the region less prone to ascites accumulation even in the supine position, as shown. (25, 26) In contrast to the iliopsoas muscle, which is in the vicinity of the peritoneal cavity, the erector spinae muscle is located outside the peritoneal cavity and thus is not influenced by the persistence of ascites. Taking these considerations into account, the suggested measurements are available in all liver MRIs performed in patients with cirrhosis and easy to elaborate on. Importantly, these measurements might reflect active muscle mass as suggested by the correlation with follistatin, a myokine which, among secretions by different cell types, is involved in muscle hemostasis and sarcopenia, (21, 27) and the good correlation with the widely used TPMT, which has been described as a very good marker of sarcopenia. (12) Apart from practical issues, such as the availability of MRI or CT scans, MRI is suitable to dissect the quality of muscle because it is able to differentiate muscle tissue from fat tissue inside the muscle. In CT scans, lower attenuation by skeletal muscle has been associated with increased lipid infiltration of the muscle in diabetic and elderly patients. (28, 29) However, these findings have never been applied to patients with (31) CT attenuation alone might depend on hydration as, e.g., fluid overload or ascites could influence the results. (32, 33) With MRI it is possible to clearly and visually differentiate fat tissue areas within the total MA and exclude it to identify FFMA. (34) Taking this advantage of MRI into account and investigating a cohort of patients twice as large, the present study is the first to establish a distinct relationship between FFMA measured in MRI and TIPS response, the ACLF risk, and genderspecific cutoffs for the FFMA to define sarcopenia.
Furthermore, the present study demonstrated that failure to increase MA after a TIPS procedure was associated with worse outcome, as demonstrated in other studies. (30, 35) This could further confirm this method's robustness as well as its adequacy in the assessment of sarcopenia. Indeed, after a TIPS procedure, sarcopenic patients performed worse, with a lower ascites resolution rate, a higher HE rate, generally worse renal and hepatic function, and protein metabolism. This clearly confirms that the FFMA reflects metabolically active muscle and that it is influenced by impaired liver function. Impaired protein and albumin hemostasis in sarcopenic patients possibly contributes to the persistence of ascites after TIPS. (36) Moreover, this study clearly demonstrates that after TIPS the rate of HE decreases in patients without sarcopenia, while in patients with sarcopenia HE episodes occur more frequently, possibly due to the fact that muscle is an important site of ammonia reduction. This is a confirmation of a recent study in 26 TIPS patients which found that sarcopenia assessed using CT scan predicted development of HE after TIPS. (37) The present study not only confirms this report on clinically assessed overt HE in a much larger set of patients (38) but also expands it to minimal (covert) HE assessed by neuropsychometric testing. All together, these findings demonstrate the prognostic value of FFMA assessed in a routine MRI in patients who received TIPS, which could be useful to identify patients at risk of complications, who might require closer management and/or allocation to LT. Indeed, at least in our cohort, the sarcopenic patients received fewer LTs than the nonsarcopenic patients, suggesting that, among other reasons, worse outcome predicted by the presence of sarcopenia is not reflected in the current allocation system of LT, which is mainly MELD score-based.
Patients with decompensation and complications of cirrhosis, even after sufficient treatment of portal hypertension with TIPS, have a very limited prognosis. In these patients, the FFMA seems to be associated with mortality and appears to be an independent predictor of mortality, as demonstrated in the present study. Of note, while the total muscle mass, which was assessed in several other studies investigating sarcopenia using non-MRI techniques in TIPS patients, also correlated with mortality, it is not an independent predictor of mortality. This suggests that in liver cirrhosis functional muscle mass might be more important than the total MA itself. This assumption is in line with a recent report suggesting an impact of myosteatosis measured indirectly by CT attenuation in a cohort of patients evaluated for LT. (39) In fact, in the present study, analyzing only nonsarcopenic patients, no predictive markers were assessed, which underlines that in TIPS patients decreased fat-free muscle mass is closely linked to decompensation and death.
This does not come as a surprise because sarcopenic patients after TIPS showed a higher CLIF-C AD score, (1) indicating a higher risk of ACLF development, and higher levels of systemic inflammation indicated by white blood cell count. (40) Indeed, in these patients, the leading cause of death was development of fatal ACLF, mainly due to sepsis.
Although our cohort is well characterized, this study has several limitations, mainly due to the retrospective nature of the analysis and the absence of a healthy control group. Nevertheless, this study demonstrates the impact of FFMA on survival using a two-step approach (a training cohort and a validation cohort) despite the fact that we only have MRI data of 15 patients before and after TIPS. Another limitation is that follistatin levels might be unspecific in relation to muscle mass. Moreover, other studies elaborated their cutoff values based on healthy or obese oncologic patients (41) (42) (43) (44) and found similar cutoff levels for sarcopenia as we did, (8, 45) rendering our technique and our data robust and valid.
Another limitation is that our training cohort and our validation cohort were not matched. Yet, these cohorts did not differ in terms of general characteristics, laboratory parameters, or prognostic scores, except for a significantly lower proportion of alcoholic etiology in the validation cohort. This, however, might also be considered one of the study's strengths as it demonstrates the importance of FFMA for different cohorts with differently distributed etiologies of cirrhosis.
Finally, we are aware that introducing a new method does not contribute to standardization of the already diverse imaging-based definitions of sarcopenia. However, a recent approach, published as a letter to the editor, reported an intraclass coefficient correlation of 0.98 in retrospectively analyzed MA using CT and MRI of patients in a living LT donor program, (46) suggesting validity of sarcopenia diagnostics across techniques. There is no evidence for choosing the radix of the superior mesenteric artery (L1) as a landmark. However, umbilicus, L3 or L4, as previously used in CT studies, is not always in the scanning field of liver MRI. Therefore, choosing L1 contributes to a reduction in MRI investigation time and, consequently, costs. Another technical issue might arise by artifacts in MRI induced by massive ascites. (47) Due to this general MRI limitation we adapted the technique as follows: (1) L1 is more suitable than L3 and L4 because less ascites is located in the scanning field and (2) the erector spinae muscle, in contrast to the psoas muscle, is located extra-abdominally. Therefore, the results are less prone to disturbances by ascites-related artifacts, not mentioning the fact that massive ascites is usually drained before imaging.
In conclusion, this study demonstrates that MRIassessed FFMA represents active muscle, is associated with outcome after TIPS, and predicts decompensation, ACLF risk, and death in decompensated patients with cirrhosis receiving TIPS. It could be a useful tool to stratify risk in decompensated patients, especially those receiving TIPS.
